Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
City of Hope Samaritan
mi
from
Phoenix, AZ
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
City of Hope Samaritan
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Scripps Clinic/Green Hospital
mi
from
La Jolla, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Scripps Clinic/Green Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
UCSD Medical Center
mi
from
La Jolla, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
UCSD Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Emory University
mi
from
Atlanta, GA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
BMT Group of Georgia (Northside Hospital)
mi
from
Atlanta, GA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
BMT Group of Georgia (Northside Hospital)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Loyola University
mi
from
Maywood, IL
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Loyola University
mi
from
Maywood, IL
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health
mi
from
Indianapolis, IN
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Wichita CCOP
mi
from
Wichita, KA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Wichita CCOP
mi
from
Wichita, KA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Tufts - New England Medical Center
mi
from
Boston, MA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Tufts - New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
DFCI/Brigham & Women's
mi
from
Boston, MA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
DFCI/Brigham & Women's
mi
from
Boston, MA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Jewish Hospital BMT Program
mi
from
Cincinnati, OH
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Jewish Hospital BMT Program
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Oklahoma Medical Center
mi
from
Oklahoma City, OK
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Oklahoma Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Oregon Health Sciences University (A)
mi
from
Portland, OR
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Oregon Health Sciences University (A)
mi
from
Portland, OR
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Fox Chase, Temple University BMT Program
mi
from
Philadelphia, PA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Fox Chase, Temple University BMT Program
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Vanderbilt University
mi
from
Nashville, TN
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Texas MD Anderson Cancer Research Center
mi
from
Houston, TX
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Texas MD Anderson Cancer Research Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Utah BMT/University of Utah Medical School
mi
from
Salt Lake City, UT
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Utah BMT/University of Utah Medical School
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Virginia Commonwealth University/MCV Hospitals
mi
from
Richmond, VA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Virginia Commonwealth University/MCV Hospitals
mi
from
Richmond, VA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Wisconsin Hospitals and Clinics
mi
from
Madison, WI
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Wisconsin Hospitals and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  8/28/2017
Clinical Research Facility
mi
from
Los Angeles, CA
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 8/28/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  8/28/2017
Clinical Research Facility
mi
from
Bethesda, MD
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 8/28/2017
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  8/28/2017
Clinical Research Facility
mi
from
Boston, MA
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 8/28/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  8/28/2017
Clinical Research Facility
mi
from
Memphis, TN
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 8/28/2017
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  8/28/2017
mi
from
Toronto,
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 8/28/2017
mi
from
Toronto,
Click here to add this to my saved trials
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study
Status: Enrolling
Updated:  8/28/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study
Status: Enrolling
Updated: 8/28/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study
Status: Enrolling
Updated:  8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study
Status: Enrolling
Updated: 8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated:  8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated: 8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated:  8/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated: 8/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/31/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/31/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/31/2017
Mayo Clinic
mi
from
Jacksonville, FL
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/31/2017
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/31/2017
Memorial Healthcare System
mi
from
Pembroke Pines, FL
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/31/2017
Memorial Healthcare System
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/31/2017
University of Chicago
mi
from
Chicago, IL
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/31/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/31/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/31/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/31/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/31/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials